MX2021015406A - Metodos de tratamiento de la diarrea por acidos biliares. - Google Patents

Metodos de tratamiento de la diarrea por acidos biliares.

Info

Publication number
MX2021015406A
MX2021015406A MX2021015406A MX2021015406A MX2021015406A MX 2021015406 A MX2021015406 A MX 2021015406A MX 2021015406 A MX2021015406 A MX 2021015406A MX 2021015406 A MX2021015406 A MX 2021015406A MX 2021015406 A MX2021015406 A MX 2021015406A
Authority
MX
Mexico
Prior art keywords
cftr
cci
methods
bile acid
acid diarrhea
Prior art date
Application number
MX2021015406A
Other languages
English (en)
Inventor
Alan S Verkman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2021015406A publication Critical patent/MX2021015406A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Abstract

La divulgación se refiere a métodos para tratar la diarrea por ácidos biliares mediante la administración de un inhibidor de canales de cloruro de CFTR.
MX2021015406A 2019-06-12 2020-06-08 Metodos de tratamiento de la diarrea por acidos biliares. MX2021015406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860539P 2019-06-12 2019-06-12
PCT/US2020/036683 WO2020251906A1 (en) 2019-06-12 2020-06-08 Methods of treating bile acid diarrhea

Publications (1)

Publication Number Publication Date
MX2021015406A true MX2021015406A (es) 2022-01-24

Family

ID=73782233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015406A MX2021015406A (es) 2019-06-12 2020-06-08 Metodos de tratamiento de la diarrea por acidos biliares.

Country Status (11)

Country Link
US (1) US20220280514A1 (es)
EP (1) EP3982972A4 (es)
JP (1) JP2022537687A (es)
KR (1) KR20220046544A (es)
CN (1) CN114007623A (es)
AU (1) AU2020291403A1 (es)
BR (1) BR112021025048A2 (es)
CA (1) CA3139930A1 (es)
IL (1) IL288804A (es)
MX (1) MX2021015406A (es)
WO (1) WO2020251906A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
USRE48842E1 (en) * 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US10441605B2 (en) * 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JOP20190276A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة

Also Published As

Publication number Publication date
IL288804A (en) 2022-02-01
JP2022537687A (ja) 2022-08-29
KR20220046544A (ko) 2022-04-14
BR112021025048A2 (pt) 2022-02-01
WO2020251906A1 (en) 2020-12-17
CN114007623A (zh) 2022-02-01
EP3982972A1 (en) 2022-04-20
EP3982972A4 (en) 2023-10-25
CA3139930A1 (en) 2020-12-17
AU2020291403A1 (en) 2021-12-23
US20220280514A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
CR20220354A (es) Inhibidores de egfr
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MY195583A (en) Modified Homoserine Dehydrogenase and Method for Producing Homoserine Or L-Amino Acid Derived from Homoserine using the same
PH12020500655A1 (en) Compounds
CR20200228A (es) COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
AU2016263598A8 (en) Methods and kits for treating depression
PH12020551031A1 (en) Modified homoserine dehydrogenase and method for producing homoserine or l-amino acid derived from homoserine using the same
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2021010916A (es) Inhibidores rad51.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2015008982A (es) Inhibidores del canal de calcio tipo t para el tratamiento del cancer.
SG11201907720RA (en) Method for the alignment of two substrates
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
MX2017015926A (es) Uso de derivados de bencimidazol para escape acido nocturno.
MX2019010699A (es) Moduladores de la expresion de pcsk9.
EP4306173A3 (en) Compositions and methods for treating cancers
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2021012296A (es) Microorganismo que produce l-aminoacido y procedimiento de produccion de l-aminoacido mediante el uso del mismo.
GB2547812A (en) Proppant composition and method
MX2020009840A (es) Granulos que comprenden l-aminoacido y procedimiento de preparacion de los mismos.
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
MX2021015406A (es) Metodos de tratamiento de la diarrea por acidos biliares.